United Therapeutics (UTHR) Liabilities and Shareholders Equity (2009 - 2026)

United Therapeutics has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $6.7 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $6.7 billion, down 13.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.9 billion (up 3.11% YoY), and the FY2025 annual result was $7.9 billion, up 7.01% from the prior year.
• Liabilities and Shareholders Equity came in at $6.7 billion for Q1 2026 at United Therapeutics, down from $7.9 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $7.9 billion in Q2 2025 to a low of $5.4 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $6.7 billion (2024), against an average of $6.8 billion.
• Across the five-year window, Liabilities and Shareholders Equity increased 21.48% in 2023 and retreated 13.3% in 2026, its largest moves.
• United Therapeutics' Liabilities and Shareholders Equity stood at $6.0 billion in 2022, then grew by 18.57% to $7.2 billion in 2023, then gained by 2.75% to $7.4 billion in 2024, then grew by 7.01% to $7.9 billion in 2025, then slipped by 14.79% to $6.7 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $6.7 billion (Q1 2026), $7.9 billion (Q4 2025), and $7.4 billion (Q3 2025), per Business Quant data.